Risk factors for neutropenic fever in non- Hodgkin’s lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis

BACKGROUND/AIMS: Febrile neutropenia (FN) interferes with the proper chemotherapy dose density or intensity in non-Hodgkin’s lymphoma (NHL) patients. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) ± rituximab has an intermediate FN risk. Prophylactic granulocyte...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yu Ri, Kim, Soo-Jeong, Park, Yong, Oh, Sung Yong, Yun, Hwan-Jung, Mun, Yeung-Chul, Kim, Jin Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association of Internal Medicine 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435507/
https://www.ncbi.nlm.nih.gov/pubmed/34265889
http://dx.doi.org/10.3904/kjim.2020.206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435507/
https://www.ncbi.nlm.nih.gov/pubmed/34265889
http://dx.doi.org/10.3904/kjim.2020.206

Ejemplares similares